Icahn And Eastbourne Win Some, Lose Some In Amylin Match
Executive Summary
Dissident shareholders Carl Icahn and Eastbourne Capital Management have managed to snare two seats on Amylin's 12-person board of directors, enough to hold the firm's feet to the fire but not enough to command a major change of course
You may also be interested in...
As Rumors About A Potential Acquisition Fly, Elan Names Two Dissidents To Its Board
Avoiding a proxy fight, the Irish firm placed two hostile members on its board, likely spelling trouble for CEO Martin.
But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”
After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board
But Who’s Counting? Icahn Wins A Biogen Seat, Another Is “Too Close To Call”
After a drama-packed shareholder meeting on June 3, Carl Icahn claims he won two of four contested seats on the 13-person, Biogen Idec board